Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JL18008 SAD Study in Healthy Adults
NCT07629310Phase 1Completed
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Aug 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of JL18008 in human immunodeficiency virus infection (HIV) (12 arms), sponsored by Jecho Biopharmaceuticals Co., Ltd. Primary endpoint: Treatment-Emergent Adverse Events up to 56 days. Started Jun 2024; status: completed.
02
Drugs
JL18008
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07629310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07629310.